The clinical research, while rapidly growing, is still early-stage in humans
Because every patient's journey is unique, these schedules are customized
Higher-dose versions like Wegovy and Zepbound have received FDA approval specifically for obesity, fueling a market expected to boom from $2.8 billion in 2022 to over $100 billion by 2030
Semaglutide already helps control blood sugar, and taking it with these drugs increases the risk of hypoglycemia (low blood sugar)
Fish and chips, corn dogs, fried mozzarella sticks, tempura, and deep-fried anything should move to the "not right now" list for the duration of your tirzepatide protocol
Tirzepatide 2.5 mg versus other starting doses Comparing starting doses across different peptides helps contextualize why 2.5 mg is the standard entry point for tirzepatide